Fierce Pharma
FEBRUARY 6, 2024
Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. | AstraZeneca is plugging $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the United States for cancer trials and future commercial supply. In turn, AZ will create more than 150 new jobs.
MedCity News
FEBRUARY 6, 2024
The preliminary results from three clinical trials administering gene therapy to address deafness from otoferlin mutations mark inspiring and incredible progress in hearing healthcare.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 6, 2024
In a midstage trial, Eli Lilly’s star diabetes and weight-loss drug tirzepatide showed promise in fatty liver disease, a difficult-to-treat condition that doesn’t yet have an FDA-approved therapy.< | Eli Lilly's star diabetes and weight loss drug tirzepatide showed promise in fatty liver disease with a massive anti-MASH benefit accompanied by a "clinically meaningful" anti-fibrosis effect.
Pharmaceutical Technology
FEBRUARY 6, 2024
The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 6, 2024
Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP | Locked in a heated battled with Novo Nordisk’s semaglutide franchise, Eli Lilly’s tirzepatide is beginning to come into its own—both with regards to sales and amid attempts to show the dual GIP/GLP-1 agonist can strike out beyond diabetes and obesity.
Pharmaceutical Commerce
FEBRUARY 6, 2024
A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 6, 2024
Novartis’s €2.7B acquisition of MorphoSys brings two cancer drug candidates, one of which would give the pharmaceutical giant a way to stand apart from other myelofibrosis treatments. In a separate deal, MorphoSys sold to Incyte its rights to a partnered blood cancer drug.
Fierce Pharma
FEBRUARY 6, 2024
As the U.S. | The U.S. Federal Trade Commission supports a draft guidance that would allow drug pricing be factored into consideration of the government's march-in rights. And the antitrust watchdog is advocating for further scrutiny around "patent thickets" to complement the march-in provision.
MedCity News
FEBRUARY 6, 2024
Blue Cross Blue Shield of Massachusetts has launched a new reproductive health care team and has partnered with Maven Clinic for 24/7 reproductive health support.
Fierce Pharma
FEBRUARY 6, 2024
On a day when Vertex revealed trial data that indicate | On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented figures that show Trikafta remains formidable. In the fourth quarter, Trikafta raked in $2.33 billion in sales, bringing its 2023 haul to $8.9 billion, a 16% increase from 2022.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
FEBRUARY 6, 2024
Primary care is essential to living healthier lives, and we need all forms of it, from small local practices to big health systems and retail chains. Ultimately, it’s going to be all primary care hands on deck, working together to make a lasting change for the health of Americans.
Fierce Pharma
FEBRUARY 6, 2024
Shortly before Novartis revealed a $2.9 billion buyout of cancer drugmaker MorphoSys, Incyte secured its own piece of the pie. | While Incyte gained more rights to lymphoma med Monjuvi, Novartis claimed the rest of MorphoSys for €2.7B on Monday. Incyte previously bought into a Monjuvi collaboration for $750 million ahead of the drug's 2020 approval.
MedCity News
FEBRUARY 6, 2024
SaaS startup Ambience Healthcare raised $70 million from investors including OpenAI, Andreessen Horowitz, Optum Ventures and Kleiner Perkins. The San Francisco-based company offers tools to alleviate clinicians’ burnout by helping them with documentation, coding, referrals and after-visit summaries.
European Pharmaceutical Review
FEBRUARY 6, 2024
Suanfarma has announced a strategic rebranding initiative to reinforce Suanfarma’s position as a global player in the healthcare sector, both as a distributor of active pharmaceutical ingredients (APIs) and as a contract development and manufacturing organisation (CDMO) in the production of APIs. In this manner, Suanfarma´s sites, Cipan and Rovereto, are now acknowledged as part of a global and unified brand.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
FEBRUARY 6, 2024
In clinical trials, pharmaceutical companies are seeking to optimize operations and improve efficiency by automating and enhancing processes through Artificial Intelligence (AI) and Machine Learning (ML). One area where this can reap tangible benefits across clinical trials is in data processing. A typical clinical trial generates over 13,000 documents in various formats (text, voice, video, apps, and web entries), making data gathering, organization and analysis challenging.
pharmaphorum
FEBRUARY 6, 2024
Right after the official launch of the new Apple Vision Pro mixed reality headset, Cedars-Sinai has launched a generative artificial intelligence (genAI) app that will use the technology to provide mental health support for patients.
MedCity News
FEBRUARY 6, 2024
Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders.
Pharmaceutical Technology
FEBRUARY 6, 2024
Health Canada has approved Chiesi Global Rare Diseases’ MYALEPTA as a treatment for individuals with lipodystrophy, an ultra-rare condition.
MedCity News
FEBRUARY 6, 2024
The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models.
pharmaphorum
FEBRUARY 6, 2024
Vertex will use a priority review voucher to speed up FDA review of its new triple therapy for cystic fibrosis, which has just cleared a phase 3 programme
Pharmaceutical Commerce
FEBRUARY 6, 2024
Pharma Commerce's new style is built off of the back of our new and improved editorial calendar.
PharmaTimes
FEBRUARY 6, 2024
Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
FEBRUARY 6, 2024
Novartis has agreed to buy Germany's MorphoSys in a transaction that values the cancer-focused biotech at $2.
PharmaVoice
FEBRUARY 6, 2024
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
pharmaphorum
FEBRUARY 6, 2024
Gene-editing startup Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings
PharmaVoice
FEBRUARY 6, 2024
The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.
pharmaphorum
FEBRUARY 6, 2024
A $15m initiative between Pfizer and the American Cancer Society aims to tackle unequal access to care in the US.
Evolve Your Success
FEBRUARY 6, 2024
Mark Copeland joins Samuel Adeyinka to share his medical sales experience in sterile processing and infection prevention. He explains how selling a suite of products in this space allows operating rooms to solve problems efficiently, make their work easier, and even uncover issues they do not know they already have. Mark discusses the role of value analysis in improving their products and services, allowing them to properly address the ever-changing and specific needs of patients.
Pharmaceutical Commerce
FEBRUARY 6, 2024
The February issue is centered around third-party logistics providers, including new dynamics and future trends that affect this key supply chain link.
Spotio
FEBRUARY 6, 2024
Sales continues to evolve, but one thing will always stay the same: the importance of sales enablement, i.e. the process of giving sales reps the resources they need to close deals. Think about it, without a quality sales enablement plan in place, your reps won’t be as effective as they could be, which will result in lackluster sales numbers and disappointing revenue.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
293 
Let's personalize your content